Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

Bristol-Myers Squibb (BMS)

Status

Conditions: Chronic Disease; Hepatitis B

Treatments: Drug: Entecavir

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00096811

AI463-900

Details and patient eligibility

About

The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these agents is contraindicated and that have no other available treatment options.

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Hepatitis B Early Access Program